Several mechanisms of action of the anti-CRC activity of EPA have been proposed, including lipid raft modulation and altered metabolism by cyclooxygenase (COX)-1 and -2, lipoxygenases and CYP450 monooxygenases [14–17]. The gene discussed is PTGS1; the disease is colorectal carcinoma.